1、AUGUST202 5Trends in Regulatory Approval and Reimbursement for Select Countries in the Middle East and AfricaOncology Therapy Access in the Era of Personalized MedicineResearch by the IQVIA Institute in 2024 revealed geographical differences in the availability of oncology novel active substances(NA

2、S)across select EU countries,Australia,Canada,and Brazil,influenced by factors such as country-level variations in clinical data acceptance,health technology assessment(HTA)processes,clinical endpoint priorities,and manufacturer strategies.Building on these insights,trends in overall regulatory appr

3、ovals and reimbursement have been analyzed for oncology therapies indicated in solid tumors and hematological malignancies in two Gulf Cooperation Council(GCC)nations Saudi Arabia and United Arab Emirates(UAE)and three African countries Algeria,Egypt,and South Africa.Important dynamics associated wi

4、th the oncology therapy landscape such as the registration and reimbursement of selected innovative targeted therapies including antibody-drug conjugates(ADCs),bispecific antibodies(bsAbs),cell and gene therapies(CAGTs),and immuno-oncology checkpoint inhibitors have been assessed.The associated comp

5、anion diagnostic requirements to administer some of these therapies are also discussed.This report outlines the underlying factors contributing to the oncology therapy access challenges,examines their implications,and highlights ongoing country level efforts to address them.It concludes with action

6、items aimed at improving oncology therapy access.The findings are intended to support discussions on existing hurdles,showcase on-going initiatives,and guide strategies to enhance access to precision oncology therapies.This report has been developed independently by the IQVIA Institute for Human Dat